Mevion Medical Systems Delivers Revolutionary Proton Therapy Technology to the Stephenson Cancer Center at Oklahoma University.
Following a 5-day journey from Massachusetts to Oklahoma, the proton accelerator was brought into the Stephenson Cancer Center in only a few hours.
LITTLETON, MA., May 30, 2013 /BusinessWire/- – Mevion Medical Systems announced today that it has delivered the superconducting synchrocyclotron accelerator for its MEVION S250 Proton Therapy System currently under installation at the Peggy and Charles Stephenson Cancer Center at the University of Oklahoma
“Mevion is proud to bring the most advanced form of radiation treatment to Oklahoma,” said Joseph Jachinowski, Chief Executive Officer of Mevion Medical Systems. “The installation of this groundbreaking technology at the Stephenson Cancer Center is a prime example of practical proton therapy deployment; delivering modern and advanced radiation therapy treatments in a fiscally responsible way, all within a fully integrated cancer center, and with the ability to grow when patient demand requires it.”
This is the third single-room MEVION S250 proton therapy system delivered - all installed at leading academic institutions.
”We are delighted to receive this revolutionary machine that will allow us to deliver the same proton treatment as other larger conventional systems but at a fraction of the cost and size and with the most advanced clinical targeting technology” said Mike Samis, chairman of the University Hospitals Authority and Trust. “The addition of this advanced treatment option to our flagship cancer center continues to define the OU Cancer Institute as the state’s leading center of excellence.”
Following a 5-day journey from Massachusetts to Oklahoma, the proton accelerator was brought into the Stephenson Cancer Center in only a few hours and will be installed on its gantry in the next few days. The MEVION S250 is enhancing the center’s state-of-the-art radiation therapy department with a fully integrated proton therapy clinical treatment room. A second MEVION S250 treatment space has been reserved to support future clinical demand.
Until now, proton therapy has been limited to only a few institutions, because of the high-cost, large space requirements, and operation complexities of legacy proton therapy systems. Powered by a TriNiobium Core™, the MEVION S250 is a unique proton therapy system that provides the same precise, non-invasive treatment capabilities and advantages of conventional systems but with significantly reduced size, improved reliability, efficient clinical workflow, and lower implementation and operational costs. With a footprint similar to an X-ray radiation therapy device, Mevion proton therapy can be easily integrated into any existing radiation therapy department.
A specialized team from Mevion will be completing the installation in the next few months before turning it over to the new proton therapy services team at the Stephenson Cancer Center at OU, led by Dr. Terence Herman, chair of the Radiation Oncology Department at the OU College of Medicine.
About Mevion Medical Systems
Mevion Medical Systems, Inc. is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of proton therapy systems, Mevion provides innovative, safe and effective solutions by transforming advances in medical technology and science into practical clinical reality.
Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.
Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.
Visit us at www.mevion.com
Melanie M. Miller
Marketing Project Manager
Mevion Medical Systems